Clinical Trials on Relapse and / or Refractory Myeloma in United Kingdom
Total 17600 results
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
NextCure, Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic Leukemia | Relapsed or Refractory Myelodysplastic SyndromeUnited States
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
University of PennsylvaniaTerminatedRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
The University of Texas Health Science Center at...CompletedRefractory or Relapsed Solid TumorsUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Solid TumorsUnited States
-
Janssen Research & Development, LLCApproved for marketingRelapsed or Refractory Multiple MyelomaBrazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
AstraZenecaTerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML)United States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
AmgenMerck Sharp & Dohme LLCTerminatedRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingRelapsed or Refractory Solid TumorsUnited States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
-
University of WashingtonAbbVieSuspendedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Mixed Phenotype Acute Leukemia | Myeloid Neoplasm | Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia | Relapsed Acute Myeloid Leukemia | Mixed Phenotype Acute Leukemia | Relapsed Acute Biphenotypic Leukemia | Relapsed... and other conditionsUnited States
-
Merck Sharp & Dohme LLCTerminatedRelapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic LeukemiaUnited States, Israel, Spain
-
Clavis PharmaSyneos Health; Theradex; CardiaBase; Learn & ConfirmCompletedRelapsed/Refractory AMLUnited Kingdom, Spain
-
St. Jude Children's Research HospitalAbbVie; Gateway for Cancer Research; Karyopharm Therapeutics IncRecruitingRefractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous LineageUnited States
-
Medical College of WisconsinRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingRefractory and/or Relapsed Metastatic Solid TumorsUnited States
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Keystone Nano, IncMilton S. Hershey Medical Center; University of VirginiaNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, RefractoryUnited States
-
Alfred Chung, MDMerck Sharp & Dohme LLCTerminatedMultiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, RefractoryUnited States
-
University of Colorado, DenverCompletedAcute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid LeukemiaUnited States
-
Caribou Biosciences, Inc.Enrolling by invitationLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's LymphomaUnited States
-
Autolus LimitedRecruitingRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin LymphomaUnited Kingdom
-
Yale UniversityVanderbilt UniversityCompletedRelapsed/Refractory Acute Myeloid LeukemiaUnited States
-
AmgenWithdrawnRelapsed/Refractory Acute Myeloid LeukemiaUnited States
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
Oryzon Genomics S.A.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.CompletedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States
-
Cellectis S.A.RecruitingRelapsed/Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Seattle Children's Hospital2seventy bioRecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Prelude TherapeuticsCompletedAdenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...United States
-
Shanghai Fosun Pharmaceutical Industrial Development...TerminatedAdvanced Cancer | Solid Tumors | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States, Australia
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaGermany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
-
Memorial Sloan Kettering Cancer CenterRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States